Nanoparticles for combination drug therapy

Liang Ma, Manish Kohli, Andrew Smith

Research output: Contribution to journalReview article

Abstract

Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted tissues and cells. This vast level of pharmacological control is intriguing, especially from the perspective of tailoring personalized treatments with maximized therapeutic synergy for individual patients. Here, we discuss promising formulations and opportunities to employ advanced screening tools and new animal models of disease that can improve chances for successful clinical translation.

Original languageEnglish (US)
Pages (from-to)9518-9525
Number of pages8
JournalACS Nano
Volume7
Issue number11
DOIs
StatePublished - Nov 26 2013

Fingerprint

Drug therapy
chemotherapy
Packaging
Screening
Animals
drugs
Tissue
Nanoparticles
nanoparticles
Molecules
Pharmaceutical Preparations
animal models
packaging
therapy
delivery
screening
formulations
cells
molecules

ASJC Scopus subject areas

  • Engineering(all)
  • Materials Science(all)
  • Physics and Astronomy(all)

Cite this

Nanoparticles for combination drug therapy. / Ma, Liang; Kohli, Manish; Smith, Andrew.

In: ACS Nano, Vol. 7, No. 11, 26.11.2013, p. 9518-9525.

Research output: Contribution to journalReview article

Ma, Liang ; Kohli, Manish ; Smith, Andrew. / Nanoparticles for combination drug therapy. In: ACS Nano. 2013 ; Vol. 7, No. 11. pp. 9518-9525.
@article{aec349ed49e2436b8ca540f70072476e,
title = "Nanoparticles for combination drug therapy",
abstract = "Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted tissues and cells. This vast level of pharmacological control is intriguing, especially from the perspective of tailoring personalized treatments with maximized therapeutic synergy for individual patients. Here, we discuss promising formulations and opportunities to employ advanced screening tools and new animal models of disease that can improve chances for successful clinical translation.",
author = "Liang Ma and Manish Kohli and Andrew Smith",
year = "2013",
month = "11",
day = "26",
doi = "10.1021/nn405674m",
language = "English (US)",
volume = "7",
pages = "9518--9525",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Nanoparticles for combination drug therapy

AU - Ma, Liang

AU - Kohli, Manish

AU - Smith, Andrew

PY - 2013/11/26

Y1 - 2013/11/26

N2 - Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted tissues and cells. This vast level of pharmacological control is intriguing, especially from the perspective of tailoring personalized treatments with maximized therapeutic synergy for individual patients. Here, we discuss promising formulations and opportunities to employ advanced screening tools and new animal models of disease that can improve chances for successful clinical translation.

AB - Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted tissues and cells. This vast level of pharmacological control is intriguing, especially from the perspective of tailoring personalized treatments with maximized therapeutic synergy for individual patients. Here, we discuss promising formulations and opportunities to employ advanced screening tools and new animal models of disease that can improve chances for successful clinical translation.

UR - http://www.scopus.com/inward/record.url?scp=84888883621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888883621&partnerID=8YFLogxK

U2 - 10.1021/nn405674m

DO - 10.1021/nn405674m

M3 - Review article

C2 - 24274814

AN - SCOPUS:84888883621

VL - 7

SP - 9518

EP - 9525

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 11

ER -